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Snake venom metalloproteinases (SVMPs) play a prominent role in the local and systemic
manifestations of viperid snakebite envenomations. Thus, the possibility of using metal-
loproteinase inhibitors in the treatment of these envenomations is a promising therapeutic
alternative. This study assessed the ability of two metalloproteinase inhibitors, the
biphosphonate clodronate and the tetracycline doxycycline, to inhibit proteolytic,
hemorrhagic, coagulant and deﬁbrinogenating effects of Bothrops asper venom. Both
compounds were able to inhibit these activities, at concentrations in the mM range, when
incubated with venom prior to testing. However, when inhibition of hemorrhage was
assessed in assays involving independent injection of venom and drug, inhibition was
poor, even when these compounds were injected immediately after envenomation. These
ﬁndings support the concept that the effectiveness of compounds, such as clodronate and
doxycycline, whose inhibitory action on SVMPs is based on zinc chelation alone, is limited,
and stress the view that more speciﬁc molecules are required for an effective inhibition of
SVMPs in vivo.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Envenomations by snake species of the family Viperidae
are characterized by local pathological effects that develop
rapidly after the bite and, depending on the severity of the
case, may result in prominent tissue damage and sequelae.
Such local pathological events include hemorrhage, edema,
myonecrosis, dermonecrosis and blistering (Gutie´rrez and
Lomonte, 2003; Warrell, 2004). In addition, viperid
snakebite envenomations often concur with systemic
alterations, i.e. coagulopathy and bleeding, which may lead
to hemodynamic disturbances and shock (Otero et al.,
2002; Warrell, 2004). Many of these local and pathological
effects are due to the action of snake venom metal-
loproteinases (SVMPs), which are zinc-dependentþ506 2920485.
cavado).
. All rights reserved.endopeptidases that belong to the ‘reprolysin’ group of
metalloproteinases (Fox and Serrano, 2005). SVMPs are
abundant in viperid snake venoms and, on the basis of their
domain composition, are classiﬁed into groups P-I to P-IV.
In general, SVMPs comprising domains additional to the
basic catalytic domain, especially those belonging to group
P-III, exert potent hemorrhagic or clotting effects (Fox and
Serrano, 2005; Gutie´rrez et al., 2005).
The key role played by SVMPs in the pathophysiology of
viperid snake envenomations has prompted the search for
inhibitors of these enzymes, with the rationale that abro-
gation of SVMP-induced effects may represent an effective
therapeutic strategy which could complement antivenom
administration in themanagement of these envenomations
(Gutie´rrez et al., 1999, 2007). There are abundant inhibitors
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mammalian metalloproteinases, especially matrix metal-
loproteinases (MMPs), which are known to play key roles in
the pathogenesis of many diseases, from cancer to inﬂam-
matory conditions (Folgueras et al., 2004; Liu et al., 2006;
Ganea et al., 2007), being also involved in dermonecrosis
induced by Loxosceles sp. spider envenomation (Paixa˜o-
Cavalcante et al., 2007). MMPs are grouped together with
astacins, reprolysins and serralysins, within the super-
family of ‘metzincins’, characterized by similar structural
features at the catalytic site (Bode et al., 1993). Such simi-
larity between MMPs and SVMPs opens the possibility that
inhibitors developed against MMPs may also be effective
against SVMPs. Such hypothesis has been demonstrated for
several synthetic inhibitors which have been shown to
effectively neutralize enzymatic and toxic activities of
SVMPs (Escalante et al., 2000; Howes et al., 2007).
Two groups of molecules that constitute effective MMP
inhibitors are biphosphonates and tetracyclines. Biphosph-
onates, such as clodronate, are synthetic compounds that
show high afﬁnity for the hydroxyapatite crystals of bone.
They inhibit various MMPs by sequestering the zinc present
at the catalytic site of these enzymes, in addition to other
actions related with MMP expression and activation
(Teronen et al., 1999). Clodronate has been used therapeu-
tically for preventing metastasis of osteolytic tumors, and
also against osteoporosis and multiple myeloma (Heikkila¨
et al., 2002). On the other hand, the tetracycline doxycycline
is an effective MMP inhibitor with diverse clinical applica-
tions which do not depend on its antibiotic effect (Acharya
et al., 2004). Its mechanism of action is based on a combi-
nation of zinc chelation and inhibition of MMP expression
(Acharya et al., 2004). The demonstrated effectiveness of
clodronate and doxycycline againstMMPs, togetherwith the
fact that they are being used at the clinical setting, prompted
us to evaluate their capacity to inhibit local and systemic
activities of the venomof the snake Bothrops asperwhich are
known to depend on the action of SVMPs.
2. Materials and methods
2.1. Venom and inhibitors
The venom of B. asper was a pool obtained from adult
specimens collected in the Paciﬁc region of Costa Rica.
Venom was lyophilized and stored at 40 C. Clodronate
and doxycycline were purchased from Sigma–Aldrich
(St. Louis, MO).
2.2. Experimental animals
Mice of the strain CD-1 were used throughout the study.
All experimental protocols involving mice were approved
by the Committee for the Use and Care of Laboratory
Animals (CICUA) of the University of Costa Rica.
2.3. Inhibition of proteolytic activity
Proteolytic activity was tested on azocasein (Wang et al.,
2004; Escalante et al., 2006). Venom (12 mg) dissolved in
10 mL of 25 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.4 wasincubated with 100 mL of a 5-mg/mL azocasein solution
(Sigma–Aldrich). After incubation at 37 C for 90 min, the
reaction was stopped by the addition of 200 mL of 5% tri-
chloroacetic acid. After centrifugation at 100 g, 100 mL of
supernatant was diluted with 100 mL of 0.5 M NaOH, and
the absorbance at 450 nm was recorded. The absorbances
of samples of azocasein incubated with buffer alone were
subtracted from the values of absorbances of samples
incubated with venom. For inhibition experiments, various
concentrations of clodronate (5–200 mM) or doxycycline
(5–80 mM) were incubated with a ﬁxed concentration of
venom for 30 min at 22–25 C. Then, proteolytic activity
was determined as described above. Controls included
venom incubated without inhibitors, inhibitors incubated
without venom, and buffer alone.
2.4. Inhibition of hemorrhagic activity
2.4.1. Experiments with preincubation
Mixtures containing a ﬁxed amount of B. asper venom
and various concentrations of either clodronate (from 25 to
200 mM) or doxycycline (from 12.5 to 200 mM) were
prepared, using PBS as diluent. Controls included mixtures
of venom and PBS, and inhibitors and PBS. After 30 min of
incubation at 22–25 C, aliquots of 100 mL of the mixtures,
containing 15 mg venom (which corresponds to 10
minimum hemorrhagic doses, Gutie´rrez et al., 1985), were
injected intradermally, in the ventral abdominal region,
into groups of four mice (18–20 g). One hour after injection,
mice were sacriﬁced by CO2 inhalation, their skins were
removed and the hemorrhagic area determined (Gutie´rrez
et al., 1985).
2.4.2. Experiments with independent injection
Groups of mice (18–20 g) were injected intramuscularly
(i.m.) in the right thigh with 50 mg venom, dissolved in
50 mL PBS. Immediately, 50 mL of PBS containing various
concentrations of either clodronate or doxycycline (from 25
to 200 mM), were administered i.m. in the same region
where venom had been injected. Controls included mice
injected with venom and then PBS, and mice injected with
PBS and then with the inhibitors. In some experiments,
injections were performed in the gastrocnemius muscle.
One hour after injection, mice were sacriﬁced by CO2
inhalation and the injected muscles were dissected out,
weighed, cut with a razor blade into small pieces and
placed in 1.5 mL of Drabkin solution (Rucavado et al., 2000).
After an overnight incubation at 4 C, aliquots of 1.2 mL
each sample were centrifuged at 2000 g for 5 min, and
then 1 mL of supernatant was diluted with 1 mL Drabkin,
and the absorbances at 540 nmwere recorded. Hemoglobin
concentration was estimated against a standard curve, and
expressed as mg hemoglobin per g tissue. Hemorrhagic
activity was expressed as percentage, considering 100% the
hemoglobin content in muscle injected with venom and no
inhibitor.
2.5. Inhibition of coagulant activity
The minimum coagulant dose (MCD) of B. asper venom
on human citrated plasma was estimated as described
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Fig. 1. Inhibition of hemorrhagic activity of B. asper venom by clodronate (A)
and doxycycline (B). Venom (15 mg) was incubated either with PBS or with
various concentrations of the inhibitors. Then, aliquots were injected i.d. in
mice and the diameter of hemorrhagic lesions in the skin was assessed after
1 h, as described in Section 2. Controls injected with either 200 mM clodr-
onate alone or 100 mM doxycycline alone were included. Results are pre-
sented as mean SD (n¼ 4). *p< 0.05 when compared with hemorrhagic
diameters of mice injected with venom alone.
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amount of venom (1.2 mg, corresponding to 2 MCDs), dis-
solved in PBS, was incubatedwith various concentrations of
the inhibitors (from 10 to 100 mM), for 30 min at 22–25 C.
Then, 100 mL of the mixtures were added to 200 mL of
citrated human plasma, previously incubated at 37 C and
clotting times were recorded. Controls included venom
incubated without inhibitors, inhibitors incubated without
venom and PBS alone. On the basis of these results,
a different experimental setting was performed. A ﬁxed
concentration of inhibitor, selected on the basis of the
previous experiments, was incubated with varying
concentrations of venom, for 30 min at 22–25 C. Then,
100 mL of the mixtures were added to 200 mL of human
plasma, and clotting times recorded. The MCD was then
estimated as described above.
2.6. Inhibition of deﬁbrinogenating activity
The minimum deﬁbrinogenating dose (MDD) of B. asper
venom was determined as described by Gene´ et al. (1989).
Mixtures containing a ﬁxed amount of venom, and two
concentrations of either clodronate or doxycycline (25 and
50 mM), were prepared in PBS. Controls included venom
without inhibitors, inhibitors without venom and PBS
alone. After 30 min of incubation at 22–25 C, 200 mL of the
mixtures, containing 10 mg venom (2 MDD), were injected
intravenously (i.v.) in the tail vein of groups of mice (18–
20 g). After 2 h, mice were bled from the retroorbital
venous plexus, blood was placed into glass tubes and
clotting times were recorded.
2.7. Statistical analysis
The signiﬁcance of the differences of the mean values of
several experimental groups was determined by ANOVA,
followed by Tukey test. When only two groups were
compared, the Student’s t test was used.
3. Results
3.1. Inhibition of proteolytic activity
Clodronate and doxycycline were effective at inhibiting
proteolytic activity of B. asper venom on azocasein. IC50s for
these inhibitors were 69 and 16 mM, respectively.
A clodronate concentration of 200 mM completely abro-
gated proteolytic activity. In the case of doxycycline, when
using concentrations higher than 25 mM, absorbances at
540 nm increased due to the color of the inhibitor; there-
fore, concentration achieving 100% inhibition could not be
determined.
3.2. Inhibition of hemorrhagic activity
3.2.1. Assays involving preincubation of venom and inhibitors
Clodronate and doxycycline inhibited, in a dose-
dependent fashion, hemorrhagic activity of B. asper venom
in the intradermal test (Fig. 1). Estimated IC50s of these
drugs for this effect were 63 and 14 mM, respectively.
Control mice receiving 200 mM clodronate and 100 mMdoxycycline showed hyperemic areas of <3 mm diameter;
moreover, 200 mM doxycycline induced a lesion in the skin
and, therefore, inhibition could not be tested at this
concentration.
3.2.2. Assays involving independent injection
of venom and inhibitors
When clodronate or doxycycline was administered i.m.,
at the site of venom injection, only a partial reduction of
hemorrhage was achieved when administering the inhibi-
tors immediately after venom injection (Fig. 2A and B).3.3. Inhibition of coagulant activity
The minimum coagulant dose of B. asper venom was
0.6 mg. Clodronate inhibited the coagulant activity of
B. asper venom in plasma (Fig. 3). The effect of doxycycline
could not be tested because a precipitate formed when this
inhibitor was mixed with venom and plasma, precluding
the proper observation of clot formation. When the coag-
ulant activity of venom on human plasma was determined
in the presence of 100 mM clodronate, the MCD was
49 2 mg, corresponding to 82 times the MCD of venom
alone (which was 0.6 0.01 mg).
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Fig. 2. Inhibition of hemorrhagic activity of B. asper venom by clodronate (A)
or doxycycline (B) in assays involving independent injection of venom and
inhibitors. Mice were injected i.m., with 50 mg venom, in 50 mL PBS. Imme-
diately after venom injection, various concentrations of either clodronate or
doxycycline, in 50 mL PBS, were injected at the same location where venom
had been administered. Controls included mice injected with venom and
then with PBS without inhibitors. The amount of hemoglobin present in the
injected muscles was determined as described in Section 2, and hemor-
rhagic activity was expressed as percentage, considering 100% the amount of
hemoglobin present in muscle injected with venom alone. Results are pre-
sented as mean SD (n¼ 4). There was a partial, albeit not signiﬁcant
(p> 0.05) reduction in the extent of local hemorrhage with both inhibitors.
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Fig. 3. Inhibition of coagulant activity of B. asper venom by clodronate.
Venom was incubated with either PBS or various concentrations of clodro-
nate. Then, aliquots of the mixtures were added to citrated human plasma,
and coagulation times were recorded. A dose-dependent inhibition of
coagulant activity was observed. Results correspond to mean SD (n¼ 4).
*p< 0.05 when compared with coagulation time of plasma incubated with
venom without inhibitors.
Table 1
Inhibition of deﬁbrinogenating activity of B. asper venom by clodronate
and doxycyclinea
Treatment Coagulation
time (s)
PBS 89 2
Venom (10 mg) >900b
Doxycycline (25 mM) 83 1
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The minimum deﬁbrinogenating dose of B. asper venom
was 5 mg. Incubation of two MDDs of B. asper venom with
doxycycline (25 and 50 mM) completely inhibited the
deﬁbrinogenating activity of the venom (Table 1). A solu-
tion of 100 mM doxycycline induced lethality in all mice
injected. In the case of clodronate, a concentration of
50 mM was ineffective at inhibiting deﬁbrinogenation.
Concentrations of clodronate of 100 and 200 mM were
toxic to mice upon i.v. injection, inducing lethality within
the ﬁrst minutes of injection.Doxycycline (50 mM) 78 1
Venom (10 mg)þ doxycycline (25 mM) 85 1
Venom (10 mg)þ doxycycline (50 mM) 67 2
Clodronate (50 mM) 75 1
Venom (10 mg)þ clodronate (50 mM) >900
a Solutions of B. asper venom were incubated with PBS, doxycycline or
clodronate. Aliquots of the mixtures were injected i.v. in mice and, after
1 h, animals were bled and clotting times recorded. Controls received PBS,
doxycycline or clodronate alone. Results are presented as mean SD
(n¼ 4).
b In these cases, blood did not clot after 900 s of observation.4. Discussion
SVMPs play a key role in the local and systemic effects
induced by viperid snake venoms (Markland, 1998;
Gutie´rrez and Rucavado, 2000; Kamiguti, 2005). Therefore,
the development of therapeutic strategies aimed at inhib-
iting SVMPs constitutes a relevant step forward for
improving the treatment of snakebite envenomations(Gutie´rrez et al., 2007). In the case of local tissue damage,
the possibility of using enzyme inhibitors in the ﬁeld,
rapidly after the onset of envenomation, has been raised
(Borkow et al., 1997; Rucavado et al., 2000; Gutie´rrez et al.,
1999, 2007), since such intervention would abrogate the
action of these enzymes before signiﬁcant tissue damage
has been inﬂicted, and before these toxins are distributed
systemically. Such rapid inhibition would be followed by
the administration of antivenoms in health centers which
usually occur several hours after the bite (Arroyo et al.,
1999). The fact that many inhibitors for MMPs have been
developed and tested in the clinical setting for a number of
diseases allows for the assessment of such inhibitors
against SVMPs. Clodronate and doxycycline are well-
known MMP inhibitors used in various diseases and whose
activity is based, among other suggested mechanisms, on
the chelation of the zinc atom present at the catalytic
center of metalloproteinases (Teronen et al., 1999; Acharya
et al., 2004). Thus, these drugs are of potential value for
A. Rucavado et al. / Toxicon 52 (2008) 754–759758snakebite envenomings, especially since they are readily
accessible and relatively cheap.
Proteolytic activity of B. asper venom on azocasein was
inhibited by clodronate and doxycycline, thus conﬁrming
previous observations with batimastat and CaNa2EDTA
(Rucavado et al., 2000) and indicating that SVMPs are
greatly responsible for proteolysis by this venom. More-
over, when incubated with venom before injection, these
inhibitors are effective in the neutralization of hemorrhagic
activity of B. asper venom,which is known to depend on the
action of SVMPs (Bjarnason and Fox, 1994; Gutie´rrez et al.,
2005). A number of hemorrhagic SVMPs have been isolated
from B. asper venom. The most abundant SVMP is the P-I
enzyme BaP1 (Gutie´rrez et al., 1995;Watanabe et al., 2003),
although the most potent hemorrhagic enzymes are the
high molecular mass P-III SVMPs BaH1 and BaH4 (Borkow
et al., 1993; Franceschi et al., 2000). Moreover, the effec-
tiveness of clodronate and doxycycline to inhibit coagulant
activity of B. asper venom on plasma and deﬁbrinogenating
activity (in the case of doxycycline) can also be explained
by the observation that SVMPs are the most important
coagulant components in this venom (Rucavado et al.,
2004). A prothrombin-activating SVMP, named basparin A,
has been characterized from this venom (Lorı´a et al., 2003).
Thrombin-like serine proteinases are also present in
B. asper venom (Arago´n and Gubensek, 1978; Pe´rez et al.,
2008), but they seem to play a secondary role in the
coagulopathy inﬂicted by this venom (Rucavado et al.,
2004, 2005), probably due to their low concentration in the
venom (Pe´rez et al., 2008).
Inhibitory concentrations of clodronate and doxycycline
when tested against B. asper venom are in the mM range,
similarly to the inhibitory concentrations of other chelating
compounds such as N4EDTA and CaNa2EDTA (Ownby et al.,
1975; Borkow et al., 1997; Rucavado et al., 2000). In
contrast, more speciﬁc metalloproteinase inhibitors, such
as the peptidomimetic hydroxamate batimastat and other
synthetic compounds, are effective SVMP inhibitors in
the mM range (Escalante et al., 2000; Rucavado et al., 2000;
Howes et al., 2007). Clearly, inhibition based on zinc-
chelating action alone requires higher concentration than
more speciﬁc inhibitors, to block venom enzymes. More-
over, since most chelating agents also sequester other
cations such as Ca2þ, they are toxic when administered in
high concentrations. This was observed in the present
study when using concentrations of clodronate and doxy-
cycline higher than 100 mM. An exception is CaNa2EDTA,
which is of low toxicity (Rucavado et al., 2000) owing to its
inability to chelate Ca2þ. This EDTA salt is used in the
treatment of lead poisoning (Klaassen, 1990; Tandon et al.,
1998).
When inhibition assays were performed with a protocol
that reproduces the actual circumstances of snakebite, i.e.
when venom is injected and the inhibitor is administered
immediately after envenomation at the site of venom
injection, inhibition of hemorrhagic activity in muscle is
achieved only to a partial extent. Similar ﬁndings were
described with CaNa2EDTA (Rucavado et al., 2000). It is
suggested that such inability to completely abrogate local
hemorrhage is due to the non-speciﬁcity of the mechanism
of inhibition by chelating agents. Thus, when injected invivo, it is likely that chelating molecules are rapidly diluted
and bind to cations in the tissues, thus precluding the
interaction of these compounds with the zinc at the cata-
lytic site of SVMPs. In these circumstances, their inhibitory
potential against venom enzymes is greatly diminished,
even when injected rapidly after envenomation. In
contrast, a more effective inhibition of local hemorrhage is
achieved when the peptidomimetic hydroxamate batima-
stat was tested (Escalante et al., 2000; Rucavado et al.,
2000). This molecule mimics the cleavage site of collagen,
thus highly increasing its afﬁnity for the catalytic site of
metalloproteinases (Bottomley et al., 1998). Since the
hydroxamate moiety of batimastat chelates the catalytic
zinc, this combination of structural features greatly
enhances the inhibitory potential of this type of inhibitor,
when compared with inhibitors based on ion chelation
only. Accordingly, batimastat, and probably other similar
peptidomimetic inhibitors, is highly effective at abrogating
hemorrhagic activity of SVMPs even when injected after
envenomation (Escalante et al., 2000; Rucavado et al.,
2000).
In conclusion, our observations demonstrate that the
biphosphonate clodronate inhibits proteolytic, hemor-
rhagic and coagulant activities of B. asper venom, and the
tetracycline doxycycline is effective in the inhibition of
proteolytic, hemorrhagic and deﬁbrinogenating activities,
when incubated with venom before testing, albeit
requiring high, i.e. mM concentrations to exert their action.
Such low activity might hamper their potential usefulness
in snakebite envenomations as shown hereby in experi-
ments involving independent injection of venom and
inhibitor. It is suggested that the search for SVMP inhibitors
that could be tested for viperid snakebite envenomations in
the clinical setting should be centered on more speciﬁc
molecules, such as peptidomimetics, which are able to
inhibit SVMPs in the nM or mM ranges, and which have
a good safety proﬁle.Acknowledgements
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